Effect of Erythropoietin on the treatment of Anemia of prematurity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711031162N10

Enrollment

Registered

2009-04-01

Start date

2001-05-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of prematurity. Anaemia of prematurity

Interventions

Intervention 1: Intervention group: erythropoietin 500 unite/kg twice in week along with supplementary iron. Intervention 2: Control group: only supplementary iron for 4 weeks.

Treatment - Drugs

Control group: only supplementary iron for 4 weeks

Intervention group: erythropoietin 500 unite/kg twice in week along with supplementary iron

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Gestational age less than 34 weeks, breast milk feeding, hematocrite <30% when infants age was between 2 to 3 weeks or HCT<25% when infants age was more than 3 weeks. Exclusion criteria: Infants with hemolytic anemia, active bleeding or congenital malformation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hemotocrite and reticulocyte count. Timepoint: at the beginning, third day from the start day and one week after the end of treatment. Method of measurement: venous sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ashraf mohammadzadeh

Neonatal Research Center

mohamadzadeha@mums.ac.ir+98 51 1852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026